[
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b001",
    "text": "October 20, 2000  -  Joint Meeting of the",
    "bbox": [
      192.8,
      71.2,
      419.2,
      85.5
    ],
    "font_size": 12.0,
    "font_name": "Arial,Bold",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b002",
    "text": "Nonprescription Drugs & Gastrointestinal Advisory Committees",
    "bbox": [
      93.0,
      85.6,
      519.1,
      102.6
    ],
    "font_size": 14.2,
    "font_name": "Arial,Bold",
    "label": "HH1"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b003",
    "text": "Food and Drug Administration",
    "bbox": [
      240.0,
      101.2,
      372.0,
      113.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b004",
    "text": "Center for Drug Evaluation and Research",
    "bbox": [
      214.5,
      113.2,
      398.2,
      125.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b005",
    "text": "Holiday Inn, 2 Montgomery Avenue, Gaithersburg, MD",
    "bbox": [
      186.0,
      124.5,
      426.6,
      136.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b006",
    "text": "Prilosec 1(omeprazole magnesium, Astra Zeneca & Procter & Gamble, NDA 21-229)",
    "bbox": [
      64.5,
      135.0,
      546.7,
      150.0
    ],
    "font_size": 12.0,
    "font_name": "Arial,Bold",
    "label": "HH2"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b007",
    "text": "Currently, there are two classes of drugs, antacids and acid reducers (histamine-2 receptor antagonists),",
    "bbox": [
      57.8,
      162.0,
      518.9,
      174.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b008",
    "text": "available in the OTC market to treat heartburn.  Both antacids and acid reducers are indicated for the treatment",
    "bbox": [
      57.8,
      173.2,
      547.5,
      185.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b009",
    "text": "of acute occasional heartburn symptoms. The acid reducers have an additional claim for the prevention of meal",
    "bbox": [
      57.8,
      185.2,
      548.9,
      197.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b010",
    "text": "induced heartburn symptoms if ingested at specified times prior to a meal. At today’s meeting, the sponsor is",
    "bbox": [
      57.8,
      196.5,
      537.7,
      208.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b011",
    "text": "seeking the approval of omeprazole in the OTC setting for these indications and for the additional indication of",
    "bbox": [
      57.8,
      207.8,
      543.7,
      219.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b012",
    "text": "24-hour prevention of heartburn.  Omeprazole, a proton-pump inhibitor, is currently indicated Rx for the",
    "bbox": [
      57.8,
      219.8,
      512.9,
      231.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b013",
    "text": "treatment of duodenal and gastric ulcer, symptomatic Gastroesophageal Reflux Disease (GERD), erosive",
    "bbox": [
      57.8,
      231.0,
      521.9,
      243.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b014",
    "text": "esophagitis, and pathological hypersecretory conditions.  In support of the proposed OTC marketing, the",
    "bbox": [
      57.8,
      242.2,
      518.2,
      254.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b015",
    "text": "sponsor conducted studies to evaluate the efficacy of omeprazole 10 mg and 20 mg for the treatment of acute",
    "bbox": [
      57.8,
      254.2,
      542.9,
      266.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b016",
    "text": "symptomatic heartburn (studies 092, 095, 017, 018, 019), for the prevention of meal induced heartburn (studies",
    "bbox": [
      57.8,
      265.5,
      548.2,
      277.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b017",
    "text": "005 and 006) and for the 24 hour prevention of heartburn (studies 171 and 183).  They also conducted five",
    "bbox": [
      57.8,
      276.8,
      527.9,
      288.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b018",
    "text": "actual use studies (studies 003, 067, 014, 022 and 091) to evaluate consumer usage patterns and dosing",
    "bbox": [
      57.8,
      288.8,
      523.4,
      300.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b019",
    "text": "compliance.",
    "bbox": [
      57.8,
      300.0,
      109.5,
      312.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b020",
    "text": "A. In studies 092 and 095, the primary endpoint for efficacy was the occurrence of sustained complete relief of",
    "bbox": [
      57.8,
      323.2,
      550.4,
      335.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b021",
    "text": "the first treated episode of heartburn.  Based on the primary measure of efficacy, is there a clinically",
    "bbox": [
      75.8,
      334.5,
      516.7,
      346.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b022",
    "text": "significant improvement of acute symptomatic heartburn in either the 10 or 20-mg omeprazole groups",
    "bbox": [
      75.8,
      345.8,
      522.7,
      357.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b023",
    "text": "compared to placebo? Please explain your answer.",
    "bbox": [
      75.8,
      357.8,
      301.4,
      369.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b024",
    "text": "B. In studies 005 and 006, the primary endpoint for efficacy was the percentage of subjects heartburn-free over",
    "bbox": [
      57.8,
      392.2,
      554.2,
      404.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b025",
    "text": "the entire four-hour period after a provocative meal.",
    "bbox": [
      75.8,
      403.5,
      303.0,
      415.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b026",
    "text": "1. Based on the primary measure of efficacy, is there a clinically significant improvement of heartburn",
    "bbox": [
      75.8,
      414.8,
      528.7,
      426.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b027",
    "text": "symptoms in either the 10 or 20 mg omeprazole groups compared to placebo?  Please explain your",
    "bbox": [
      93.8,
      426.8,
      533.9,
      438.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b028",
    "text": "answer.",
    "bbox": [
      93.8,
      438.0,
      127.6,
      450.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b029",
    "text": "2. Are the analyses of the pre-specified secondary endpoints supportive of the primary study outcome?",
    "bbox": [
      75.8,
      449.2,
      537.7,
      461.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b030",
    "text": "Do they add information regarding clinically significant treatment effect?",
    "bbox": [
      93.8,
      461.2,
      410.2,
      473.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b031",
    "text": "C. In studies 171 and 183, the primary endpoint for efficacy was the complete prevention of heartburn between",
    "bbox": [
      57.8,
      483.8,
      552.7,
      495.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b032",
    "text": "the first two doses of therapy.",
    "bbox": [
      75.8,
      495.8,
      206.2,
      507.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b033",
    "text": "1. Based on the primary measure of efficacy, is there a clinically significant improvement of heartburn",
    "bbox": [
      75.8,
      507.0,
      528.7,
      519.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b034",
    "text": "symptoms in either the 10 or 20 mg omeprazole groups compared to placebo?  Please explain your",
    "bbox": [
      93.8,
      518.2,
      533.9,
      530.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b035",
    "text": "answer.",
    "bbox": [
      93.8,
      530.2,
      127.6,
      542.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b036",
    "text": "2. Are the analyses of the pre-specified secondary endpoints supportive of the primary study outcome?",
    "bbox": [
      75.8,
      541.5,
      537.7,
      553.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b037",
    "text": "Do they add information regarding clinically significant treatment effect?",
    "bbox": [
      93.8,
      552.8,
      410.2,
      564.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b038",
    "text": "D. Based on the types and frequency of adverse events reported in the clinical trials and in the post-marketing",
    "bbox": [
      57.8,
      576.0,
      548.2,
      588.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b039",
    "text": "adverse events database, are the safety concerns for the OTC marketing of omeprazole able to be",
    "bbox": [
      75.8,
      587.2,
      510.7,
      599.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b040",
    "text": "addressed solely by labeling (identifying risks) to consumers for (a) short term or (b) chronic intermittent",
    "bbox": [
      75.8,
      599.2,
      531.7,
      611.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b041",
    "text": "use? In answering this question, please consider the reports of anaphylaxis/angioedema/urticaria, liver",
    "bbox": [
      75.8,
      610.5,
      527.9,
      622.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b042",
    "text": "toxicity, white blood cell disorders and severe skin reactions.",
    "bbox": [
      75.8,
      621.8,
      342.7,
      633.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b043",
    "text": "E. Do other safety concerns affect acceptability of the OTC marketing of omeprazole? In answering this",
    "bbox": [
      57.8,
      645.0,
      519.7,
      657.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b044",
    "text": "question, please consider the questions raised by the FDA reviewer regarding: 1) the masking of serious",
    "bbox": [
      75.8,
      656.2,
      536.2,
      668.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b045",
    "text": "disease; 2) the potential for genotoxicity, tumorigenicity,  and fetal and developmental toxicity; 3) rebound",
    "bbox": [
      75.8,
      668.2,
      540.7,
      680.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b046",
    "text": "hyperacidity reported in the literature with discontinuation of therapy; and 4) hypergastrinemia that may be",
    "bbox": [
      75.8,
      679.5,
      542.9,
      691.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 1,
    "block_id": "986_p1_b047",
    "text": "associated with the chronic or chronic intermittent use of omeprazole.",
    "bbox": [
      75.8,
      690.8,
      381.6,
      702.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b001",
    "text": "F. Are there drug-drug interactions that affect acceptability of OTC marketing of omeprazole?",
    "bbox": [
      57.8,
      71.2,
      473.9,
      83.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b002",
    "text": "G. In the actual use studies, approximately 65% of the subset of subjects using the product only for the",
    "bbox": [
      57.8,
      105.8,
      516.0,
      117.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b003",
    "text": "prevention of heartburn exceeded the 10 consecutive day limit for dosing recommended on the label.",
    "bbox": [
      75.8,
      117.8,
      521.2,
      129.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b004",
    "text": "(Note: 19% to 22% of consumers using omeprazole for both acute symptoms and prevention similarly",
    "bbox": [
      75.8,
      129.0,
      524.2,
      141.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b005",
    "text": "exceeded the 10 consecutive day limit for dosing recommended on the label).  Do these results suggest that",
    "bbox": [
      75.8,
      140.2,
      552.7,
      152.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b006",
    "text": "omeprazole will likely be used by consumers on a chronic basis for conditions other than episodic heartburn",
    "bbox": [
      75.8,
      152.2,
      551.9,
      164.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b007",
    "text": "(e.g. GERD)?   Is the treatment of GERD an acceptable OTC indication?",
    "bbox": [
      75.8,
      163.5,
      396.7,
      175.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b008",
    "text": "H. Based on the results of the actual use and label comprehension studies, has the sponsor presented",
    "bbox": [
      57.8,
      186.8,
      515.2,
      198.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b009",
    "text": "adequate data to substantiate that consumers will be able to use omeprazole appropriately in the OTC",
    "bbox": [
      75.8,
      198.0,
      527.2,
      210.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b010",
    "text": "setting for: 1) acute symptomatic treatment; 2) prevention for up to 10 days.",
    "bbox": [
      75.8,
      209.2,
      409.4,
      221.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b011",
    "text": "In responding, consider these factors:",
    "bbox": [
      75.8,
      232.5,
      242.2,
      244.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b012",
    "text": "a) The ability of consumers to appropriately self-select.",
    "bbox": [
      93.8,
      243.8,
      342.7,
      255.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b013",
    "text": "b) The ability of consumers to use the correct dosage and for the period of time specified in the label.",
    "bbox": [
      93.8,
      255.8,
      545.2,
      267.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b014",
    "text": "c) The ability of consumers to identify when they should see a physician before using the product and",
    "bbox": [
      93.8,
      267.0,
      547.4,
      279.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b015",
    "text": "once they have begun using the product.",
    "bbox": [
      111.8,
      278.2,
      292.4,
      290.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b016",
    "text": "d) The ability of consumers to identify serious adverse events.",
    "bbox": [
      93.8,
      290.2,
      374.2,
      302.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b017",
    "text": "e) The ability of consumers to avoid interacting drugs.",
    "bbox": [
      93.8,
      301.5,
      337.4,
      313.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b018",
    "text": "Use in women of childbearing age or in the pediatric population.",
    "bbox": [
      111.8,
      312.8,
      392.2,
      324.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b019",
    "text": "Has the sponsor provided sufficient evidence to support the approval of omeprazole 10 mg and/or 20 mg for",
    "bbox": [
      75.8,
      336.0,
      551.9,
      348.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b020",
    "text": "use in the OTC setting for:",
    "bbox": [
      75.8,
      347.2,
      191.2,
      359.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b021",
    "text": "1. Acute symptomatic heartburn?  Please explain.",
    "bbox": [
      75.8,
      359.2,
      301.4,
      371.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b022",
    "text": "2. Prevention of episodic or chronic heartburn? Please explain.",
    "bbox": [
      75.8,
      370.5,
      359.2,
      382.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b023",
    "text": "a) If yes to either, are there any additional studies or risk management programs needed post-",
    "bbox": [
      93.8,
      381.8,
      516.7,
      393.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b024",
    "text": "approval?",
    "bbox": [
      111.8,
      393.8,
      155.8,
      405.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b025",
    "text": "b) If no, what additional studies or risk management programs are necessary to support approval for",
    "bbox": [
      93.8,
      405.0,
      542.9,
      417.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b026",
    "text": "OTC marketing?",
    "bbox": [
      111.8,
      416.2,
      185.1,
      428.3
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b027",
    "text": "J. If the Committee recommends approval of omeprazole for use in the OTC setting, please discuss any",
    "bbox": [
      57.8,
      439.5,
      522.7,
      451.5
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b028",
    "text": "recommendations regarding information to be conveyed in labeling (e.g., to help consumers select between",
    "bbox": [
      75.8,
      450.8,
      549.7,
      462.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b029",
    "text": "omeprazole and other currently available OTC products, and to help consumers use omeprazole safely and",
    "bbox": [
      75.8,
      462.8,
      549.7,
      474.8
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  },
  {
    "pdf_id": "986",
    "page_number": 2,
    "block_id": "986_p2_b030",
    "text": "effectively).",
    "bbox": [
      75.8,
      474.0,
      125.2,
      486.0
    ],
    "font_size": 9.8,
    "font_name": "Arial",
    "label": "BODY"
  }
]